Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 22Neoplasm Metastasis 17Lung Neoplasms 10Carcinoma, Hepatocellular 10Prostatic Neoplasms 9Melanoma 9Carcinoma, Renal Cell 9Carcinoma, Non-Small-Cell Lung 9Liver Neoplasms 8Sarcoma 7Kidney Neoplasms 7Pain 6Colorectal Neoplasms 5Esophageal Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Small Cell Lung Carcinoma 3Osteosarcoma 3Neoplasms 3Keratosis, Actinic 3Cholangiocarcinoma 3Carcinoma, Ductal, Breast 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Desmoid Tumors 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2

Interventions

Oxaliplatin 29Fluorouracil 25Leucovorin 20Capecitabine 18Irinotecan 17Bevacizumab 14Cisplatin 12Surveys and Questionnaires 11Gemcitabine 9Drug Therapy 9Standard of Care 8Nivolumab 7Cetuximab 7pembrolizumab 6S 1 (combination) 6Cyclophosphamide 6atezolizumab 5Specimen Handling 5Endoscopic Mucosal Resection 5Educational Status 5Docetaxel 5Blood Specimen Collection 5fludarabine 4aldesleukin 4Radiotherapy 4Radiosurgery 4Pemetrexed 4IFL protocol 4Folfox protocol 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastrointestinal Neoplasms × Cryosurgery × Clear all
NCT01065441 2020-01-22

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

Mirror Biologics, Inc.

Phase 1/2 Completed
9 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡